Literature DB >> 25954087

Reversibility and heritability of liver fibrosis: Implications for research and therapy.

Hussein M Atta1.   

Abstract

Liver fibrosis continues to be a major health problem worldwide due to lack of effective therapy. If the etiology cannot be eliminated, liver fibrosis progresses to cirrhosis and eventually to liver failure or malignancy; both are associated with a fatal outcome. Liver transplantation, the only curative therapy, is still mostly unavailable. Liver fibrosis was shown to be a reversible process; however, complete reversibility remains debatable. Recently, the molecular markers of liver fibrosis were shown to be transmitted across generations. Epigenetic mechanisms including DNA methylation, histone posttranslational modifications and noncoding RNA have emerged as major determinants of gene expression during liver fibrogenesis and carcinogenesis. Furthermore, epigenetic mechanisms have been shown to be transmitted through mitosis and meiosis to daughter cells and subsequent generations. However, the exact epigenetic regulation of complete liver fibrosis resolution and inheritance has not been fully elucidated. This communication will highlight the recent advances in the search for delineating the mechanisms governing resolution of liver fibrosis and the potential for multigenerational and transgenerational transmission of fibrosis markers. The fact that epigenetic changes, unlike genetic mutations, are reversible and can be modulated pharmacologically underscores the unique opportunity to develop effective therapy to completely reverse liver fibrosis, to prevent the development of malignancy and to regulate heritability of fibrosis phenotype.

Entities:  

Keywords:  DNA methylation; Epigenetics; Epimutations; Hepatic stellate cells; Histone modification; Inheritance; Liver cirrhosis; Long noncoding RNA; MicroRNA; Transcription regulation

Mesh:

Substances:

Year:  2015        PMID: 25954087      PMCID: PMC4419054          DOI: 10.3748/wjg.v21.i17.5138

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  94 in total

1.  MeCP2 controls the expression of RASAL1 in the hepatic fibrosis in rats.

Authors:  Hui Tao; Cheng Huang; Jing-Jing Yang; Tao-Tao Ma; Er-Bao Bian; Lei Zhang; Xiong-Wen Lv; Yong Jin; Jun Li
Journal:  Toxicology       Date:  2011-10-25       Impact factor: 4.221

2.  Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis.

Authors:  J P Iredale; R C Benyon; M J Arthur; W F Ferris; R Alcolado; P J Winwood; N Clark; G Murphy
Journal:  Hepatology       Date:  1996-07       Impact factor: 17.425

3.  Osteopontin expression in normal and fibrotic liver. altered liver healing in osteopontin-deficient mice.

Authors:  Dionne Lorena; Ian A Darby; Alain-Pierre Gadeau; Laetitia Lam Shang Leen; Susan Rittling; Luís C Porto; Jean Rosenbaum; Alexis Desmoulière
Journal:  J Hepatol       Date:  2005-08-15       Impact factor: 25.083

4.  Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver.

Authors:  Jan Harder; Oliver G Opitz; Jan Brabender; Manfred Olschewski; Hubert E Blum; Shuji Nomoto; Henning Usadel
Journal:  Int J Cancer       Date:  2008-06-15       Impact factor: 7.396

Review 5.  Endocrine disruptor induction of epigenetic transgenerational inheritance of disease.

Authors:  Michael K Skinner
Journal:  Mol Cell Endocrinol       Date:  2014-07-31       Impact factor: 4.102

Review 6.  Molecular therapy for hepatic injury and fibrosis: where are we?

Authors:  Colette C Prosser; Roy D Yen; Jian Wu
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

7.  microRNA are Central Players in Anti- and Profibrotic Gene Regulation during Liver Fibrosis.

Authors:  Andrea Noetel; Monika Kwiecinski; Natalia Elfimova; Jia Huang; Margarete Odenthal
Journal:  Front Physiol       Date:  2012-03-19       Impact factor: 4.566

8.  The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease.

Authors:  Stéphanie Patouraux; Stéphanie Bonnafous; Cosmin S Voican; Rodolphe Anty; Marie-Christine Saint-Paul; Maria-Alessandra Rosenthal-Allieri; Hélène Agostini; Micheline Njike; Nadége Barri-Ova; Sylvie Naveau; Yannick Le Marchand-Brustel; Pascal Veillon; Paul Calès; Gabriel Perlemuter; Albert Tran; Philippe Gual
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

9.  Mutant MMP-9 and HGF gene transfer enhance resolution of CCl4-induced liver fibrosis in rats: role of ASH1 and EZH2 methyltransferases repression.

Authors:  Hussein Atta; Mahmoud El-Rehany; Olfat Hammam; Hend Abdel-Ghany; Maggie Ramzy; Martin Roderfeld; Elke Roeb; Ayman Al-Hendy; Salama Abdel Raheim; Hatem Allam; Heba Marey
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

10.  MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis.

Authors:  Jelena Mann; David C K Chu; Aidan Maxwell; Fiona Oakley; Nian-Ling Zhu; Hidekazu Tsukamoto; Derek A Mann
Journal:  Gastroenterology       Date:  2009-10-17       Impact factor: 22.682

View more
  21 in total

1.  Silencing of EPCAM suppresses hepatic fibrosis and hepatic stellate cell proliferation in mice with alcoholic hepatitis via the PI3K/Akt/mTOR signaling pathway.

Authors:  Zhi Zhang; Huiqing Wen; Jun Weng; Lei Feng; Hongya Liu; Xiaojun Hu; Fanhong Zeng
Journal:  Cell Cycle       Date:  2019-08-05       Impact factor: 4.534

Review 2.  Evolving Insights on Metabolism, Autophagy, and Epigenetics in Liver Myofibroblasts.

Authors:  Zeribe C Nwosu; Hamed Alborzinia; Stefan Wölfl; Steven Dooley; Yan Liu
Journal:  Front Physiol       Date:  2016-06-01       Impact factor: 4.566

3.  Non-invasive evaluation of liver stiffness after splenectomy in rabbits with CCl4-induced liver fibrosis.

Authors:  Ming-Jun Wang; Wen-Wu Ling; Hong Wang; Ling-Wei Meng; He Cai; Bing Peng
Journal:  World J Gastroenterol       Date:  2016-12-14       Impact factor: 5.742

4.  Presence of atrial fibrillation is associated with liver stiffness in an elderly Finnish population.

Authors:  Aki Juhani Käräjämäki; Olli Kettunen; Samuli Lepojärvi; Olli-Pekka Koivurova; Y Antero Kesäniemi; Heikki Huikuri; Olavi Ukkola
Journal:  PLoS One       Date:  2017-03-13       Impact factor: 3.240

5.  Tanshinol ameliorates CCl4-induced liver fibrosis in rats through the regulation of Nrf2/HO-1 and NF-κB/IκBα signaling pathway.

Authors:  Rong Wang; Jing Wang; Fuxing Song; Shengnan Li; Yongfang Yuan
Journal:  Drug Des Devel Ther       Date:  2018-05-17       Impact factor: 4.162

6.  Evaluation of liver fibrosis with a monoexponential model of intravoxel incoherent motion magnetic resonance imaging.

Authors:  Cuiyun Chen; Fangfang Fu; Jing Zhang; Fangfang Guo; Meiyun Wang; Shaocheng Zhu; Dapeng Shi; Yuwei Tian
Journal:  Oncotarget       Date:  2018-05-15

7.  Isochlorogenic Acid A Attenuates the Progression of Liver Fibrosis Through Regulating HMGB1/TLR4/NF-κB Signaling Pathway.

Authors:  Xin Liu; Kai Huang; Ru Jiao Zhang; Dan Mei; Bo Zhang
Journal:  Front Pharmacol       Date:  2020-05-01       Impact factor: 5.810

8.  Diffusion tensor imaging quantifying the severity of chronic hepatitis in rats.

Authors:  Mengping Huang; Xin Lu; Xiaofeng Wang; Jian Shu
Journal:  BMC Med Imaging       Date:  2020-07-02       Impact factor: 1.930

9.  Stem Cell Therapy for Cirrhosis of Liver in Bangladesh: Specific Design Compatible for Developing Country.

Authors:  Mamun Al Mahtab; Sheikh Mf Akbar; Masuda Begum; Md A Islam; Md A Rahim; Sheikh M Noor-E-Alam; Md A Alam; Faiz A Khondaker; Ahmed L Moben; Masuda Mohsena; Md Sakirul I Khan; Md Z Huq; Swati Munshi; Ashraful Hoque; Sheikh A Haque
Journal:  Euroasian J Hepatogastroenterol       Date:  2019-02-01

10.  CD147 Promotes CXCL1 Expression and Modulates Liver Fibrogenesis.

Authors:  Wen-Pu Shi; Di Ju; Hao Li; Lin Yuan; Jian Cui; Dan Luo; Zhi-Nan Chen; Huijie Bian
Journal:  Int J Mol Sci       Date:  2018-04-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.